Scientists from the Brain Chemistry Labs found a new way to detect Alzheimer’s disease with a blood test.
The research is published in PLOS ONE and was conducted by Dr. Sandra Banack et al.
Although symptoms of advanced Alzheimer’s disease are well known, diagnosis of Alzheimer’s disease in its earliest stages requires careful cognitive testing by neurologists.
The discovery of a unique ratio of metabolites from blood samples of early-stage Alzheimer’s patients promises to speed diagnosis, allowing earlier treatments to be initiated.
In the study, the team found that the ratio of two molecules, 2-aminoethyl dihydrogen phosphate and taurine, allows them to reliably discriminate samples of early-stage Alzheimer’s patients.
The blood samples were drawn from patients enrolled in an FDA-approved Phase II trial at Dartmouth Hitchcock Medical Center in New Hampshire and then shipped to the Brain Chemistry Labs for analysis.
Current attempts to diagnose Alzheimer’s disease from blood samples depend on the presence of amyloid fragments, the molecules that cause brain tangles and plaques.
The team considers amyloid plaques to be a consequence rather than the cause of Alzheimer’s disease
What is exciting about this new discovery is that it does not depend on amyloid and the assay can be performed on analytical equipment that is already present in most large hospitals.
Sign up for our newsletter for more information about this topic.
If you care about Alzheimer’s disease, please read studies about the root cause of cognitive decline in Alzheimer’s, and this herb compound could fight COVID-19, Alzheimer’s disease.
For more information about brain health, please see recent studies about best aromatherapy herb for Alzheimer’s disease, and results showing 5 steps to protect against Alzheimer’s and Dementia.
Copyright © 2022 Knowridge Science Report. All rights reserved.
